Bayer Intellectual Property Gmbh

Schering Aktiengesellschaft

Bayer Aktiengesellschaft

Bayer Healthcare LLC

Bayer Schering Pharma Ag

Bayer Pharma Aktiengesellschaft

Michael Gottfried

Michael Lögers

Joachim Rehse

Werner Heilmann

Juergen Stiehl

Saskia Wichmann

Jens Geisler

Matthias Schneider

Leslaw Mleczko

Wolfgang Schmidt

Tomoyuki Ando

Stephan Schubert

Georg Rossling

Gabriele Winter

Ilja Peckermann

Hans-Ulrich Moritz

Jan-Peter Ingwersen

Ekkehard Barth

Kai Lovis

Andreas Briel

Jens Stefan Roggan

Konstantinos Metaxas

Hilmar Weinmann

Uwe Budde

Masaru Honjo

Joji Suzuki

The present invention relates to a process for preparing 4-{4-[({[4-chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, its salts and monohydrate.

Process for the preparation of 4-(4-amino-3-fluorophenoxy)-N-methylpyyridine-2-carboxamide

A method of reacting phosgene with a second compound containing one or more of hydroxyl, thil, amino and/or formamide groups, wherein phosgene has a GHS hazard identification of GHS06 and is obtainable from the reaction of carbon monoxide and chlorine and wherein the second compound is capable of a chemical reaction with phosgene is provided.

Method for the phosgenation of compounds comprising hydroxyl, thiol, amino and/or formamide groups

The present invention relates to a process for preparing 4-(4-[({[4-chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy)-N-methylpyridine-2-carboxamide, its salts and monohydrate.

[object Object]

The crystalline Polymorph B of N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxy-carbonyaminomethyl]benzamide (MS-275) of formula I is described, as well as the process for the production of said compound, and its use as a medicament for the treatment of selected diseases.

N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B

A process for the production of high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]-piperazin-1-yl}-2,2-diphenylethan-1-one fumarate as well as rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]piperazin-1-yl}-2,2-diphenylethan-1-one fumarate at a purity of at least 98.55% is described.

Process for the production of high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]-piperazin-1-yl}-2,2-diphenylethan-1-one fumarate and high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]piperazin-1-yl}-2,2-diphenylethan-1-one fumarate

The invention relates to a multi-stage method for producing gas-filled microcapsules. In one stage of the method, the substance that forms the coat is polymerized. The microcapsules are formed in a physically and/or temporally separate stage, by means of a structuring process. The polymerization is carried out with moderate stirring, while the microcapsules are structured in dispersing conditions.

Multi-stage method for producing gas-filled microcapsules

Growing community of inventors

Wuppertal, Germany

Michael Gottfried